Pineal Peptides (Epitalon, Epithalamin): Research Evidence and Regulatory Status

Key Takeaways

• Compounds covered: Epithalamin (natural pineal extract), epitalon / epithalon (synthetic tetrapeptide Ala-Glu-Asp-Gly)
• Research area: Circadian melatonin rhythm changes in aging; proposed pineal gland function modulation
• Evidence range: Small uncontrolled human and primate studies from Khavinson and colleagues reporting associations with melatonin rhythm normalization; animal longevity data; in vitro telomerase observations in human cell lines; no independently conducted Phase 3 RCT
• Regulatory range: Not FDA-approved for any indication; epitalon not eligible for 503A compounding under current bulk drug substance framework; epithalamin (bovine tissue extract) categorically ineligible for 503A
• Baseline biomarkers relevant to age-related sleep changes: Cortisol (circadian function), TSH (thyroid), IGF-1 (GH-axis/aging), hs-CRP (inflammation), vitamin B12 (melatonin synthesis pathway)
• As of April 2026: No FDA-approved indication exists for any pineal peptide; FDA has signaled removal of Category 2 peptide nominations, which further narrows — rather than creates — any access pathway.
• Bottom line: Pineal peptides have a small, sleep-relevant human research footprint concentrated in age-related circadian melatonin changes. The evidence base is limited, comes from a single research group, has not been replicated in independently conducted Phase 3 trials, and the compounds are not lawfully available through FDA-regulated channels in the US.

Understanding the Pineal Gland and Sleep: The Biology

The pineal gland is a small (roughly 150 mg) endocrine organ located in the posterior forebrain, positioned outside the blood-brain barrier. It functions as the body's primary transducer of photoperiodic information — translating the light-dark cycle into endocrine signals that synchronize circadian rhythms throughout the body.

Melatonin is the pineal gland's primary secretory product. Its synthesis follows a well-characterized pathway: light detected by retinal photoreceptors suppresses melatonin production through the retinohypothalamic tract and SCN; darkness releases this inhibition, triggering melatonin synthesis from serotonin via N-acetyltransferase and hydroxyindole-O-methyltransferase (HIOMT). The resulting nocturnal melatonin surge signals darkness to peripheral tissues, the brain, and the hypothalamus — reinforcing circadian alignment.

With age, the pineal gland undergoes progressive calcification and cellular changes that reduce both the amplitude of the nocturnal melatonin surge and the precision of its circadian timing. This age-related pineal decline is associated with sleep consolidation problems, reduced slow-wave depth, and circadian fragmentation — conditions common in adults over 60. A 2002 review by Khavinson and Golubev in Advances in Gerontology pineal gland aging and longevity, establishing the biological foundation for the pineal peptide research program.

A 1997 review by Steiger and Holsboer in Sleep placed melatonin and pineal-related regulation in the context of neuropeptide sleep modulation, framing the pineal-sleep relationship within the broader neuropeptide landscape. Peptides are relevant to this system because the pineal gland's gene expression — including the synthesis enzymes for melatonin — is regulated by peptide signaling cascades that become less responsive with age.

Pineal Peptides Studied in Research: A Quick Comparison

The following peptides have published evidence relevant to pineal function and age-related circadian regulation. The primary research program is from Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology.

• Compound: Epithalamin (natural pineal polypeptide extract)
  Proposed mechanism: Hypothesized influence on pineal melatonin production via modulation of hypothalamic-pituitary-pineal signaling; circadian rhythm normalization reported in small uncontrolled human studies
  Evidence: Small uncontrolled human studies reporting melatonin rhythm changes in elderly subjects; primate data; long-term observational human mortality report in combination with thymalin
  FDA status: Not FDA-approved for any indication. Bovine pineal tissue extract; categorically ineligible as a bulk drug substance for 503A compounding because it is not a component of an FDA-approved drug, is not the subject of a USP/NF monograph, and is not on the FDA bulk substances list
  SP availability: Not offered by Superpower
  Administration in research: Parenteral administration in published studies
• Compound: Epitalon / Epithalon (Ala-Glu-Asp-Gly)
  Proposed mechanism: Synthetic tetrapeptide derived from epithalamin's most active sequence; hypothesized (not demonstrated) influence on pineal gene expression that could theoretically support endogenous melatonin production; same single-group evidence base as epithalamin for melatonin-related observations
  Evidence: In vitro cell line studies of telomerase activity; animal longevity data; small human observational sleep-related melatonin studies; no independent Phase 3 RCT
  FDA status: Not FDA-approved for any indication. Not on the FDA list of bulk drug substances approved for 503A compounding, not USP/NF, not a component of any FDA-approved drug. Was placed by FDA in Category 2 of bulk drug substance nominations; FDA has signaled removal of Category 2 nominations in April 2026
  SP availability: Not offered by Superpower
  Administration in research: Parenteral administration in published studies

Neither compound listed has completed the Phase 3 clinical trial process required for FDA approval. Their inclusion here is for educational context only.

Epitalon: The Research in Detail

Epitalon's research program is the most developed of the pineal peptide category, spanning cellular studies, animal models, and small human clinical observations. The evidence base is largely concentrated in a single research group.

Melatonin rhythm observations

The most directly sleep-relevant evidence for epitalon comes from studies of melatonin rhythm observations in aging subjects. A 2007 study by Korkushko, Khavinson, and colleagues published in Advances in Gerontology melatonin rhythm normalization in elderly subjects — establishing the primary citation for epitalon's melatonin-normalizing signal. A 2004 study by Korkushko, Khavinson, and colleagues in Bulletin of Experimental Biology and Medicine reported associations between epithalamin treatment and normalization of circadian melatonin rhythm metrics in elderly subjects. A 2003 study by Goncharova, Khavinson, and colleagues in Advances in Gerontology reported peptide-associated changes in age-related pineal disturbances in monkeys, providing the primate data supporting the human findings. [Small human studies / primate data]

A 2005 study by Goncharova, Khavinson, and colleagues in Experimental Gerontology reported preclinical findings suggesting pineal peptides may influence age-related changes in hormonal functions of both the pineal gland and pancreas, suggesting broader endocrine-related effects at the preclinical level. These findings collectively suggest a plausible biological hypothesis: age-related pineal decline reduces melatonin amplitude; pineal peptides may partially attenuate this decline by influencing pineal gene expression. The mechanism is not fully characterized. The human studies are small. Independent replication in adequately powered, placebo-controlled trials does not exist.

Antioxidant and cellular observations

Epitalon's proposed mechanisms extend to antioxidant activity in the pineal system. A 2007 study by Kozina, Khavinson, and colleagues in Archives of Gerontology and Geriatrics antioxidant activity of pineal peptides in vitro, with performance in some assays comparable to or greater than melatonin in the same assay conditions — a narrow in vitro finding that does not translate directly to clinical antioxidant benefit. This is relevant to the pineal biology context because oxidative stress in the aging pineal gland is proposed to contribute to its declining melatonin output.

A 1997 study by Anisimov and colleagues in Mechanisms of Ageing and Development reported that melatonin and epithalamin together extended life span and reduced free-radical oxidation in Drosophila, suggesting a potential synergistic relationship at the model-organism level. A 2022 study by Yue and colleagues in Aging reported in a mouse model that epitalon was associated with reduced markers of post-ovulatory aging-related damage in oocytes, demonstrating an antioxidant-related signal at the cellular level in a different biological context. [In vitro / Animal study]

Telomerase and cellular aging

A research direction distinct from sleep concerns cellular aging markers. A 2003 study by Khavinson, Bondarev, and Butyugov in Bulletin of Experimental Biology and Medicine telomerase activity in human somatic cells. This is an in vitro (cell culture) finding; it has not been shown to translate into clinically meaningful anti-aging effects in humans in controlled trials. A 2025 study by Al-Dulaimi and colleagues in Biogerontology reported that epitalon increased telomere length in human cell lines through telomerase upregulation or ALT activity. A 2004 study by Khavinson and colleagues in the Bulletin of Experimental Biology and Medicine reported that in cell-culture conditions, epitalon was associated with extended replicative capacity in human somatic cell lines beyond the typical Hayflick division limit — an in vitro finding that has not been demonstrated to translate to clinical outcomes in humans. [In vitro / Cell line data]

These findings are from cell line experiments, not controlled human trials of aging or longevity outcomes. The gap between in vitro telomerase activation and clinically meaningful anti-aging effects in humans has not been bridged by controlled trial evidence.

Longevity and long-term observational data

The most clinically discussed — and most preliminary — finding in the Khavinson research program is a long-term observational study. A 2003 report by Khavinson and Morozov published in Neuroendocrinology Letters described an uncontrolled 15-year observational follow-up in elderly subjects treated with combined thymalin and epithalamin alongside standard care. The study reported lower mortality in the treatment group versus comparison groups but was not a randomized, placebo-controlled trial and does not constitute evidence of life prolongation under modern regulatory standards. A related report by Khavinson and colleagues, published in Uspekhi Gerontologii in 2002, described observational geroprotective effects of thymalin and epithalamin in a long-term clinical observation. Two 2012–2013 reviews by Khavinson in Advances in Gerontology summarized clinical and experimental results from peptide bioregulators as geroprotectors. [Observational long-term study; single research group; not independently replicated]

These are not placebo-controlled randomized trials. The mortality data comes from an observational context in elderly Russian subjects treated with a combination of thymalin and epithalamin alongside standard care. The findings are hypothesis-generating and have influenced the longevity peptide community. They do not constitute proof of efficacy under modern regulatory standards.

Animal longevity models

Khavinson and colleagues published animal longevity data for epitalon across multiple model organisms. A 2003 study by Anisimov and colleagues in Biogerontology reported effects of epitalon on biomarkers of aging, life span, and spontaneous tumors in mice. A 2000 study by Khavinson and colleagues in Mechanisms of Ageing and Development reported that epitalon extended lifespan of Drosophila melanogaster. A 2010 review by Anisimov and colleagues in Biogerontology reviewed peptide bioregulation of aging results and prospects across the full program. An overview of epitalon as a bioactive pineal tetrapeptide by Araj and colleagues published in the International Journal of Molecular Sciences in 2025 provides the most current comprehensive summary. A 2002 review by Khavinson and colleagues in Neuroendocrinology Letters placed the pineal and thymic bioregulators in the broader aging research framework. [Animal study / In vitro]

Additional preclinical endocrine context: a 2012 study by Arutjunyan and colleagues in Current Aging Science reported in rats that melatonin and pineal peptides were associated with changes in impaired reproductive cycles, suggesting broader endocrine-related activity at the preclinical level.

Regulatory Status at a Glance

As of April 2026, the pineal peptides discussed in this article carry the following regulatory statuses.

• Epitalon (Ala-Glu-Asp-Gly): Not FDA-approved for any indication. Not on the FDA list of bulk drug substances approved for use in 503A compounding. Not the subject of a USP or NF monograph. Not a component of any FDA-approved drug. Was placed by FDA in Category 2 of the bulk drug substance nominations — a designation indicating FDA will not exercise enforcement discretion for its use in compounding pending further review. FDA has signaled removal of Category 2 peptide nominations in April 2026, which further narrows — rather than creates — any pathway. Compounded epitalon prepared outside these pathways is not authorized under 503A.
• Epithalamin: A bovine pineal gland tissue extract. Not FDA-approved for any indication. Not the subject of a USP or NF monograph. Not a component of any FDA-approved drug. Not on the FDA bulk drug substances list. Not eligible for compounding under Section 503A. Any product sold in the United States labeled as epithalamin is not legally distributed as a compounded prescription medication.
• Pinealon (a related peptide): Not FDA-approved and not on the FDA list of bulk drug substances approved for 503A compounding. Discussed separately on its own page.

None of these compounds have been approved by the FDA for sleep, anti-aging, longevity, or any other indication. Their presence in this article is for educational context.

Considerations When Evaluating Pineal Peptide Research

The pineal peptide research program is an internally consistent but externally unverified body of evidence. Several considerations should shape how it is understood.

Who the evidence applies to: The melatonin normalization data is specifically from elderly subjects and primates with documented age-related pineal decline. The proposed mechanism — influencing a declining biological function — does not apply in the same way to younger individuals with intact pineal function and normal melatonin amplitude. The appropriate question is not "does epitalon improve sleep" but whether the pineal-function hypothesis addresses the specific cause of disrupted sleep in any given individual.

Source concentration: The majority of the human and animal evidence comes from a single research group at one institution. Independent replication by other research groups in other countries using modern trial designs does not exist for most of the sleep and longevity claims. This is a significant limitation — not a disqualification, but a major constraint on confidence in the evidence.

Comparison with melatonin: Melatonin has a substantially more robust evidence base for sleep, extensive OTC availability, and meta-analytic data supporting its use for circadian-related sleep disruption specifically. The evidence gap between melatonin and pineal peptides is substantial. A provider would typically evaluate whether melatonin's evidence-based role in circadian normalization has been adequately explored. Investigational compounds without an FDA-authorized US pathway are not a routine next step.

Regulated US pathways: Epitalon is not available through any FDA-authorized commercial pathway in the United States. It is not FDA-approved, is not eligible for 503A compounding under current bulk drug substance pathways, and is not sold as a dietary supplement (injectable peptides are not lawful dietary supplements under DSHEA). For older adults with sleep disruption who might otherwise consider investigational compounds, baseline biomarker testing — including cortisol diurnal profiling, thyroid panel, IGF-1, and a comprehensive metabolic panel — characterizes the conventional, addressable causes of poor sleep (HPA axis dysregulation, thyroid dysfunction, GH-axis decline, B12 deficiency) before any investigational direction is considered.

Safety Considerations

Published human safety data for epitalon comes from the Khavinson research group's clinical observation studies. No systematic, independent adverse event reporting exists. Long-term human safety data from placebo-controlled trials does not exist.

Parenteral administration in general carries universal risks: injection-site reactions, sterility requirements, and contamination risk from unregulated sources. Epitalon products sold through online research-chemical vendors are labeled for research use only and are not lawful for human administration under the intended-use doctrine. FDA has not evaluated any epitalon product — research-use-only or otherwise — for identity, purity, or potency in humans. Compounding pharmacies also cannot lawfully produce epitalon for human use under the current 503A bulk drug substance framework.

Situations in which the absence of data is most acute:

• Pregnancy and breastfeeding: no reproductive safety data exists for any pineal peptide in humans.
• Active or history of hormone-sensitive malignancy: endogenous melatonin has complex, incompletely characterized interactions with hormone-sensitive cancers; compounds hypothesized to influence pineal melatonin signaling have not been evaluated in this population.
• Concurrent use of melatonin supplements or other sleep agents: additive effects on circadian signaling have not been studied.
• Products sourced from unregulated vendors: products labeled "research use only" are not lawful for human administration and have not been evaluated by the FDA for identity, purity, or potency.

This list describes where data gaps are most significant for investigational pineal peptide research. It is not a pharmaceutical contraindications or precautions profile; no such profile exists for any pineal peptide because none is FDA-approved or subject to FDA-evaluated labeling.

Consult a licensed provider before considering any compounded peptide formulation.

Baseline Biomarkers Relevant to Age-Related Sleep Changes

Baseline biomarker testing helps establish whether age-related pineal decline is contributing to sleep disruption, and distinguishes it from other systemic causes. Without this context, there is no objective basis for characterizing the cause of sleep disruption or for selecting among interventions.

• Cortisol (diurnal): HPA axis dysregulation is a primary driver of circadian disruption and frequently mimics or compounds pineal-related sleep problems. A morning and evening cortisol pattern characterizes whether the HPA axis is the more proximate cause of sleep disruption — relevant before attributing poor sleep to pineal decline.
• TSH and thyroid panel: Hypothyroidism causes fatigue and sleep-quality deterioration that can be misattributed to melatonin deficiency. Baseline TSH helps rule out thyroid dysfunction before considering pineal-related hypotheses.
• IGF-1: The GH-sleep relationship is well established — GH pulses occur during slow-wave sleep, and GH-axis decline in aging contributes to reduced slow-wave depth independently of melatonin. A baseline IGF-1 level characterizes GH-axis status and is relevant for any evaluation of the aging endocrine system.
• hs-CRP: Systemic inflammation activates the HPA axis and reduces slow-wave sleep independently of circadian melatonin status. Baseline hs-CRP characterizes inflammatory burden as a potential contributor to poor sleep quality.
• Vitamin B12: B12 deficiency impairs the conversion of serotonin to melatonin — a correctable cause of melatonin production decline that may present similarly to age-related pineal dysfunction in bloodwork-naive evaluation. Testing vitamin B12 helps rule out deficiency before attributing melatonin rhythm problems to the pineal gland.
• Comprehensive metabolic panel: Liver and kidney function baselines are common safety prerequisites in any peptide context. Glucose and HbA1c characterize metabolic status relevant to the aging context in which pineal peptides have been studied.

For older adults experiencing sleep disruption consistent with age-related circadian changes, cortisol diurnal pattern, TSH, IGF-1, and B12 together identify whether the disruption is driven by HPA axis dysregulation, thyroid changes, GH-axis decline, or B12 deficiency — all addressable with conventional approaches.

Regulated Access Pathways for Pineal Peptides

No FDA-reviewed commercial channel exists for epitalon in the United States. Epitalon is not FDA-approved, is not eligible for 503A compounding under current bulk drug substance pathways, and is not a lawful dietary supplement. Epithalamin, as a bovine tissue extract, is not eligible for 503A compounding by compound class.

Epitalon products sold through online research-chemical vendors are labeled for research use only and are not lawful for human administration under the intended-use doctrine. FDA has not evaluated any epitalon product for identity, purity, or potency in humans. Any US consumer access is through channels that operate outside the FDA-regulated drug supply.

Melatonin — available OTC, with a more substantial evidence base for circadian sleep normalization — is a conventional, FDA-regulated option with established evidence. The two compounds are not interchangeable, but melatonin's evidence base and regulatory status are considerably more established.

Understanding Your Baseline

Pineal peptide research illustrates the challenge of evaluating promising but incompletely validated biology. The melatonin rhythm observations from Khavinson and colleagues are internally consistent across multiple small studies from a single research group spanning decades, but have not been independently replicated. The absence of independent Phase 3 replication is a genuine limitation, and the US regulatory pathway for epitalon is closed under the current bulk drug substance framework. In that gap, baseline biomarker data does the most productive work — identifying whether the specific cause of sleep disruption is pineal-related, and whether conventional, better-evidenced approaches have been fully explored.

That testing-first principle is central to Superpower's approach to preventive health. Whether the conversation with a provider leads to melatonin supplementation, cortisol management, or B12 repletion, the starting point is the same: knowing where your biomarkers stand before selecting any intervention.

IMPORTANT SAFETY INFORMATION

Epitalon (Ala-Glu-Asp-Gly) is not approved by the FDA for any medical use. Research has been conducted primarily by a single research group and consists of small human observational studies, primate data, and animal experiments. Its safety, efficacy, appropriate dosing, and long-term effects in humans have not been established through adequately powered, independently replicated clinical trials. Epitalon is not on the FDA list of bulk drug substances approved for use in 503A compounding, is not the subject of a USP or NF monograph, and is not a component of any FDA-approved drug. FDA placed epitalon in Category 2 of the bulk drug substance nominations and has signaled removal of Category 2 nominations in April 2026. Compounded epitalon prepared outside these pathways is not authorized under 503A. No FDA-reviewed commercial channel exists for epitalon.

Epithalamin (natural bovine pineal extract) is not FDA-approved for any indication. As a bovine tissue extract, it is not a component of any FDA-approved drug, is not the subject of a USP or NF monograph, and is not on the FDA bulk drug substances list. It is not eligible for compounding under Section 503A.

Situations in which the absence of data is most acute include pregnancy and breastfeeding (no reproductive safety data); active or history of hormone-sensitive malignancy (melatonin-pathway interactions in this population have not been characterized); concurrent use of melatonin or other sleep agents (additive effects on circadian signaling are unstudied); and products obtained from unregulated vendors (not lawful for human administration and not evaluated by the FDA for identity, purity, or potency). These reflect data gaps in the research literature, not a pharmaceutical contraindications or precautions profile — no such profile exists for any pineal peptide.

Long-term human safety data from placebo-controlled trials does not exist for any pineal peptide. No systematic, independent adverse event profile has been established. This page is provided for educational purposes only and does not constitute medical advice or an endorsement of use.

Disclaimer: Epitalon and epithalamin are not FDA-approved for any indication. Epitalon is not eligible for 503A compounding under the current bulk drug substance framework; epithalamin is not eligible by compound class. The research supporting these compounds consists primarily of small studies from a single research group without independent Phase 3 replication. This educational content is for informational purposes only.